A collaboration between Plaquetec Ltd. and a lab at the Babraham Institute has demonstrated the druggability of a pro-inflammatory protein discovered by Plaquetec.
Researchers from Indiana University presented data from a study that aimed to assess the therapeutic potential of interleukin-9 (IL-9) blockade in the context of lung cancer.
Researchers from Xiangya Hospital of Central South University published data from a study that explored potential treatment targets for cutaneous squamous cell carcinoma (cSCC) by investigating the regulatory mechanisms of follistatin-like 1 (FSTL1), which has been shown to be implicated in a variety of cancers.
Researchers from Huazhong University of Science and Technology and collaborators published results from a study that aimed to assess the potential role of caveolin 3 (CAV3) in mitochondrial function during diabetic cardiomyopathy (DCM).
Pancreatic ductal adenocarcinoma (PDAC) has a poor prognosis, in part due to the immunosuppression surrounding the tumor mediated by regulatory T cells (Tregs), thus preventing effective responses to immune therapy.
Chemokine CXCL5 is an inflammatory mediator and a powerful neutrophil chemoattractant, which mainly acts through CXCR2 to produce its biological effects.
Scientists from the Centre for Genomic Regulation and collaborators have developed a new approach to limiting the amount of collagen produced by hyperactive fibroblasts, which could lead to effective treatments for fibrotic diseases and scarring.
RNA-binding proteins (RBPs) have emerged as interesting targets for cancer therapy. There is growing evidence that RBPs are dysregulated in cancer, usually with abnormal expression and/or with the presence of mutations.
